Molecular pathogenesis of neuroendocrine tumors: Implications for current and future therapeutic approaches Journal Article


Authors: Oberg, K.; Casanovas, O.; Castaño, J. P.; Chung, D.; Delle Fave, G.; Deng̀efle, P.; Harris, P.; Khan, M. S.; Kulke, M. H.; Scarpa, A.; Tang, L. H.; Wiedenmann, B.
Article Title: Molecular pathogenesis of neuroendocrine tumors: Implications for current and future therapeutic approaches
Abstract: The treatment landscape and biologic understanding of neuroendocrine tumors (NET) has shifted dramatically in recent years. Recent studies have shown that somatostatin analogues have the potential not only to control symptoms of hormone hypersecretion but also have the ability to slow tumor growth in patients with advanced carcinoid. The results of clinical trials have further shown that the VEGF pathway inhibitor sunitinib and the mTOR inhibitor everolimus have efficacy in patients with advanced pancreatic NETs. The efficacy of these targeted therapies in NET suggests that the molecular characterization of NETs may provide an avenue to predict both which patients may benefit most from the treatment and to overcome potential drug resistance. Recent genomic studies of NETs have further suggested that pathways regulating chromatin remodeling and epigenetic modification may play a key role in regulating NET growth. These observations offer the potential for new therapeutic and diagnostic advances for patients with NET. ©2013 AACR.
Journal Title: Clinical Cancer Research
Volume: 19
Issue: 11
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2013-06-01
Start Page: 2842
End Page: 2849
Language: English
DOI: 10.1158/1078-0432.ccr-12-3458
PROVIDER: scopus
PUBMED: 23459719
DOI/URL:
Notes: --- - "Export Date: 1 July 2013" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Laura Hong Tang
    447 Tang